Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
March 27, 2024 16:17 ET
|
Orchestra BioMed Holdings, Inc.
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with...
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
March 26, 2024 08:00 ET
|
Orchestra BioMed Holdings, Inc.
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales,...
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
March 13, 2024 08:00 ET
|
Orchestra BioMed Holdings, Inc.
New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining...
Orchestra BioMed to Participate in Upcoming Investor Conferences
March 07, 2024 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
March 06, 2024 08:37 ET
|
Orchestra BioMed Holdings, Inc.
Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate...
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
February 26, 2024 08:00 ET
|
Orchestra BioMed Holdings, Inc.
8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study Orchestra BioMed is...
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 16:21 ET
|
Orchestra BioMed Holdings, Inc.
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patientsBACKBEAT pivotal...
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
September 19, 2023 07:30 ET
|
Orchestra BioMed Holdings, Inc.
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an...
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:34 ET
|
Orchestra BioMed Holdings, Inc.
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in...
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
August 08, 2023 08:30 ET
|
Orchestra BioMed Holdings, Inc.
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US...